A Study of LY900014 Compared to Insulin Lispro (Humalog) in Adults With Type 2 Diabetes

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 628 participants.

Also called NCT03952143

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 628 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT03952143
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
Argentina, China, Mexico (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT03952143. Randomized; double masking; primary purpose treatment. Start 2019-05-27 (actual); primary completion 2021-01-20 (actual). Results posted on 2022-02-08.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study of LY900014 Compared to Insulin Lispro (Humalog) in Adults With Type 2 Diabetes
Condition
Type 2 Diabetes Mellitus
Intervention (Drug)
LY900014
Intervention (Drug)
Insulin Lispro
Intervention (Drug)
Insulin Glargine
Intervention (Drug)
Insulin Degludec
Lead sponsor
Eli Lilly and Company (class: industry)

Record details

Record id
cardio:ct-nct03952143
Content hash
227913a7d9b9dcf21ae7377f5d404f236b7dd5355b86d05e1c422852163a420d